quetiapine

(redirected from Seroquel XR)
Also found in: Medical.

quet·i·a·pine

 (kwə-tī′ə-pēn′)
n.
An antipsychotic drug, C21H25N3O2S, that acts as an antagonist of multiple neurotransmitters including serotonin and norepinephrine and is used in its fumarate form to treat schizophrenia and bipolar disorder.

[que-, origin unknown + t(h)ia(ze)pine, one of its chemical constituents (thi(o)- + az(o)- + ep(oxide) + -ine).]
Translations

quetiapine

n quetiapina
Mentioned in ?
References in periodicals archive ?
The drugs Claxton and Perdue were promoting, Seroquel and Seroquel XR, are used to treat schizophrenia, major depressive disorder and bipolar disorder.
This can be attributed mainly to the expirations of patents for Eli Lilly's Cymbalta, Otsuka Pharmaceutical/BMS' Abilify and AstraZeneca's Seroquel XR.
Pharmaceutical giant AstraZeneca made slight gains after a US district court ruled its patent for depression treatment Seroquel XR was valid.
The court dismissed AstraZeneca's bid to expand patents on the medication's active ingredient, quetiapine, and on the formula for Seroquel XR, the extended-release version.
said a 12-month study enrolling 292 adult patients showed its schizophrenia treatment Latuda was not inferior to AstraZeneca PLC's Seroquel XR.
By delaying competition until then, AstraZeneca gains valuable breathing-space to allow its new version of the medicine, Seroquel XR, to capture market share.
The decline is due to key patent expiries of blockbuster drugs such as Lexapro, Cymbalta, Abilify, and Seroquel XR during the forecast period.
In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million.
Food and Drug Administration that the London-based company stop using a promotional letter for Seroquel XR - an extended release version of the medicine - that doesn't carry a diabetes warning.
Seroquel XR, one of AstraZeneca's best-selling drugs, is approved in the United States only for the treatment of people with schizophrenia or bipolar disorder.
These data highlight the market potential for therapies approved to treat MDD patients with an inadequate response to SSRIs and/or SNRIs, such as Bristol-Myers Squibb/Otsuka's atypical antipsychotic Abilify and AstraZeneca's Seroquel XR, as well as emerging therapies targeting treatment-resistant MDD.